Last updated August 22, 2026
Key finding
Fasting glucose in OGTT (mmol/L) was 5.03 ± 0.1 for MI and 4.9 ± 0.1 for PLA.
This randomized controlled trial investigated the effects of myo-inositol supplementation on the risk of gestational diabetes. The results indicated no significant differences in GDM incidence between the myo-inositol and placebo groups.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This randomized controlled trial investigated the effects of myo-inositol supplementation on the risk of gestational diabetes. The results indicated no significant differences in GDM incidence between the myo-inositol and placebo groups.
Understanding the impact of myo-inositol on gestational diabetes is crucial, as this condition affects many pregnant individuals and can lead to complications for both mother and child. While the study did not find a significant reduction in diabetes incidence, the observed changes in metabolic parameters may inform future research and dietary recommendations for pregnant women at risk.
The study did not find significant differences in GDM incidence, limiting the conclusions on effectiveness. Sample size and population characteristics may affect the generalizability of the findings. The trial's focus on metabolic parameters may not fully capture the clinical significance of myo-inositol supplementation.
Published in
Publication details and source links for this paper.
Salma HA, Ibrahim I, Hala A, et al. Myo-inositol supplementation and its effects on gestational diabetes risk: a randomized controlled trial. Frontiers in Nutrition. 2025;12:1623699. doi:10.3389/fnut.2025.1623699
No significant difference in GDM incidence between myo-inositol and placebo groups (0 incidence change, p-value: null).
Fasting glucose was lower in the myo-inositol group by 0.13 mmol/L (p-value: 0.032).
Glycemia 1h post-OGTT was 0.8 mmol/L lower in the myo-inositol group, but not statistically significant (p-value: 0.464).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Myo-inositol supplementation and 2-hour plasma glucose, Fasting Plasma Glucose (FPG), Fasting insulin levels, and 4 more.
This study contributes evidence to
Primary intervention
Myo-inositol supplementation
Primary outcomes
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
4
Related topics
7
Evidence pairs
982
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
matched_outcome
Related evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
Myo-inositol supplementation → 2-hour plasma glucose
Myo-inositol supplementation → 2-hour plasma glucose
Myo-inositol supplementation → Fasting insulin levels
Myo-inositol supplementation → Fasting insulin levels
Myo-inositol supplementation → Fasting Plasma Glucose (FPG)
Myo-inositol supplementation → Fasting Plasma Glucose (FPG)
Myo-inositol supplementation → Gestational diabetes mellitus incidence
Myo-inositol supplementation → Gestational diabetes mellitus incidence
Myo-inositol supplementation → Insulin resistance
Myo-inositol supplementation → Insulin resistance
Myo-inositol supplementation → Overall weight gain during pregnancy
Myo-inositol supplementation → Overall weight gain during pregnancy
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Myo-inositol supplementation and Postprandial and OGTT Glucose, Myo-inositol supplementation and Fasting Glucose.
This study contributes to the evidence on the following intervention-outcome relationships.
Curated evidence collections and hubs this study is part of.
All studies measuring Fasting Glucose
Measures Fasting Glucose as a key outcome.
All studies on Myo-inositol supplementation
Contributes to Myo-inositol supplementation evidence base.
All studies measuring Postprandial and OGTT Glucose
Measures Postprandial and OGTT Glucose as a key outcome.
All studies measuring Overall weight gain during pregnancy
Measures Overall weight gain during pregnancy as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
2 results
2 results
2 results
2 results
2 results
Generated from the study's connected evidence using Evidence Intelligence™.
Myo-inositol supplementation may improve fasting plasma glucose (FPG).
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Ranked evidence signals
Fasting Plasma Glucose (FPG)
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
Myo-inositol supplementation may reduce gestational diabetes mellitus incidence.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Ranked evidence signals
Gestational diabetes mellitus incidence
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
Current evidence does not show a clear benefit of Myo-inositol supplementation for 2-hour plasma glucose.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
2-hour plasma glucose
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Myo-inositol supplementation for fasting insulin levels.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Fasting insulin levels
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
